Recent Articles

• 
  Global Investment

  Celltrion Boosts Shareholder Returns With Bonus Issue, Buyback

  Panoramic view of Celltrion’s second plant. Provided by Celltrion On the 21st, Celltrion announced that it would implement a comprehensive set of market response measures to enhance shareholder value and reassess corporate value, including a bonus issue, additional share buybacks, and share acquisit

  2026.05.21
• 
  Pharmaceutical R&D

  Kolmar Korea Adapts Cancer Therapy for Targeted Anti‑Aging

  KOLMAR Korea’s Sejong plant. Courtesy of Kolmar Group KOLMAR Korea has developed a new cosmetic ingredient that selectively identifies and suppresses specific factors that accelerate aging in human skin. It is a next-generation convergence technology that organically combines the medical community’s

  2026.05.21
• 
  AI Healthcare

  Expert Column: Clear AI Rules Can Advance Korea’s Medical Competitiveness by 10 Years

  Kim Jae-seon, Professor at Dongguk University Law School (Legal Advisor, National Academy of Medicine of Korea) Radiation oncology specialists analyzing imaging reports interpreted by artificial intelligence (AI), patients visiting outpatient clinics showing arrhythmia alerts from their smartwatches

  2026.05.21
• 
  Biotech

  AI-Driven Protein Design Unlocks Virus Secrets

  A multinational research team including domestic researchers has succeeded in creating artificial protein structures using artificial intelligence (AI). On the 20th, the Ministry of Science and ICT announced that a research team led by Professor Sangmin Lee of the Department of Chemical Engineering

  2026.05.21
• 
  Biopharma

  Yuhan Thrives in APIs, KRW 210 Billion Gilead Deal

  Yuhan Corporation Central Research Institute. Courtesy of Yuhan Corporation Yuhan Corporation has signed an active pharmaceutical ingredient (API) supply contract worth more than KRW 210 billion with global pharmaceutical company Gilead Sciences. This follows an API supply contract worth about KRW 5

  2026.05.20
• 
  AI Healthcare

  Medidata Releases Report on AI in 2026 Clinical Trials

  Medidata has released its report “The State of AI in Clinical Trials 2026.” Source: Medidata Analysis indicates that the use of AI (artificial intelligence) in clinical trials can enhance operational efficiency. Clinical trial solutions company Medidata announced on the 20th, through its report “The

  2026.05.20
• 
  AI Healthcare

  KMI Joins Government Medical AI Talent Training, Expands AI Screening Education

  At the “2026 Medical AI Healthcare Workforce Job Training Project Kick-off” held at the Korea Human Resource Development Institute for Health and Welfare on April 30, (from left) Bae Nam-young, Acting President of the Korea Human Resource Development Institute for Health and Welfare, Kim Chan-woong,

  2026.05.19
• 
  Biopharma

  Innovation Is K-Bio’s Biggest Edge, Combo Keytruda Trials Surge

  “The greatest strength of the Korean bio ecosystem is that it combines both the scale and quality of innovation. It was impressive to see the exploration of new biological mechanisms or approaches and the active willingness to take on more complex challenges.” At MSD’s “Partnering Day,” held at COEX

  2026.05.19
• 
  MedTech

  Depression-Treating Lens Aims to Heal Through Eyes

  In experiments, the research team confirmed that the contact lenses it developed produced antidepressant treatment effects. Cell Reports Physical Science An antidepressant contact lens with effectiveness comparable to that of conventional antidepressant drugs has been developed. Electrodes embedded

  2026.05.18
• 
  Vaccine

  Hantavirus With 50% Fatality Rate Lacks Vaccine

  Electron microscope image of hantavirus. It is transmitted through rodent excreta, and with no approved vaccines or treatments available, its development is urgently needed worldwide. Provided by the U.S. Centers for Disease Control and Prevention (CDC) Confirmed cases of Andes virus, a type of hant

  2026.05.18